Blue Matter’s Post

An emerging #biopharma company seeking to maximize the value of its pipeline asset(s) must communicate that value to potential investors in a compelling & credible manner. In this article, we describe 6 key success factors for communicating value to investors. >> https://lnkd.in/eDwCCXcC Authors: Vinay Torani, Pankaj Oza, Tahel Noy, & Sam Calderwood #biopharma #biotech #pharmaceuticals

For emerging #biopharma, a robust commercial proposition is essential. Following Part 1, outlining the critical components of a commercial proposition, we've just published Part 2 in our mini series, identifying 6 key success factors for communicating value to potential investors. Part 1 can also be found here: https://lnkd.in/eTbkpHsJ

What will revive #pharma dealmaking action in 2024? In this new article for PM360 by Evaluate’s Dan Chancellor, he considers whether #biotech firms can hang on for long enough for investor confidence to return. 📖 Read now: https://ow.ly/kx7b30syRUT

What will revive #pharma dealmaking action in 2024? In this new article for PM360 by Evaluate Ltd’s Daniel Chancellor he considers whether #biotech firms can hang on for long enough for investor confidence to return and what needs to happen for next year to see an upswing in investment. 📖 Read here: https://ow.ly/cSl950Ql47m

Exploring the Challenges and Opportunities in Biopharma Investing In my latest Substack article, I delve into the intriguing world of biopharma investments and why traditional private equity firms tend to shy away from this dynamic sector. Biopharma companies operate in a landscape fraught with uncertainty, from early-stage development to regulatory hurdles, making it a challenging yet rewarding arena for investors. Read my article to uncover the nuances of biopharma investing and discover the strategies for navigating risk in healthcare finance. https://lnkd.in/eSxE8PD3 #Biopharma #PrivateEquity #HealthcareInvesting #InvestmentStrategy #RiskManagement

Our newly published funding and pipeline report shows that Massachusetts not only weathered the post-pandemic industry reset with resilience but is well-positioned to remain a global powerhouse in drug research and development. It’s incredible to see local companies continue to attract substantial VC funding, while M&A activity has increased to fill the gap left by the lack of IPOs. Read the full report here: https://lnkd.in/e6mJBWt7 Our unmatched density of biotech startups, pharma companies, investors, and academic institutions translates into the delivery of life-changing therapies for patients around the world. It also, however, makes the Commonwealth’s biopharma industry more vulnerable to disruptions in the drug development life cycle from federal price controls and attacks on patents and IP. Continued partnerships between industry and government, and cross-sector collaboration, will help to mitigate certain challenges and keep the innovation engine strong.

Thoughts on this? >> Regeneron enters venture investing with $500M, poaches senior partner from ARCH >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #biotech #pharma #productmarketing

Thoughts on this? >> Int'l Biotechnology: Investors are moving back to our recession-beating sector! - Citywire Investment Trust Insider >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #competitivemarketing #biotech #healthcare #pharmaceutical

Thoughts on this? >> Int'l Biotechnology: Investors are moving back to our recession-beating sector! - Citywire Investment Trust Insider >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #competitivemarketing #pharmaceutical #biotech

Compass Carter Osborne’s Life Sciences Insights Magazine (2nd Edition) is out - a quarterly roundup of sector updates on executive appointments, groundbreaking clinical trials, investment milestones, IPOs, and M&A activities. #biotech #biopharma #investments #clinicaltrails #executivemovements #privateequity #venturecapital #funding #mergerandacquisition